ViroPharma Incorporated (VPHM)

[surf1944]

7:32AM ViroPharma beats by $0.02, beats on revs (VPHM) 11.37 : Reports Q2 (Jun) earnings of $0.34 per share, $0.02 better than the Thomson Reuters consensus of $0.32; revenues rose 33.1% year/year to $109 mln vs the $99 mln consensus. Co reports Cinryze sales of $40 mln vs. $39 mln consensus; reports Vancocin sales of $68.4 mln vs. $60 mln consensus. For the year 2010, ViroPharma expects the following: Net Cinryze sales are expected to be $165 to $175 mln. Research and development and selling, general and administrative expenses, including the impact of stock compensation expense,are expected to be $135 to $145 mln. Stock compensation expenses are expected to be between $10 and $12 mln.